Momenta Pharmaceuticals Launches Phase 2/3 Trial of M281 for the Treatment of Warm Autoimmune Hemolytic Anemia and is Granted FDA Fast Track Designation

August 1, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search